Lyka Labs gets Indian patent for Pregabalin Gel 8%

08 Apr 2025 Evaluate

Lyka Labs has been granted an Indian patent for its proprietary product, Pregabalin Gel 8%, with patent protection valid through 2043. This significant milestone reinforces the company’s focus on innovation and its leadership in developing topical drug delivery systems.

Pregabalin Gel 8%, a topical formulation designed for the effective management of diabetic neuropathic pain, received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) in October 2024 for manufacturing and marketing in India. This gel formulation represents a first-of-its-kind innovation in India, offering localized delivery of pregabalin directly at the site of pain, potentially minimizing systemic exposure and related side effects commonly associated with oral formulations.

With this patent, the company strengthens its intellectual property portfolio and reaffirms its vision to be at the forefront of innovative pharmaceutical solutions.

Lyka Labs is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions.


Lyka Labs Share Price

78.00 -3.04 (-3.75%)
05-Dec-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.00
Dr. Reddys Lab 1276.55
Cipla 1520.55
Zydus Lifesciences 933.10
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×